Lv51
1128 积分 2022-08-30 加入
Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework
9天前
已完结
International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update
1个月前
已完结
Glucagon-like Peptide-1 Receptor Agonists Are Associated With Improved Survival and Reduced Liver-Related Events in Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Liver Disease: A Large Real-World Retrospective Study
1个月前
已关闭
Multi-organ proteomic atlas of obesity regression in male mice
1个月前
已完结
Incidence of Cirrhosis in Fibrotic Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Placebo Arms from Randomized Clinical Trials
1个月前
已完结
Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis
1个月前
已完结
Glucagon induces the hepatic expression of inflammatory markers in vitro and in vivo
1个月前
已完结
Meta‐analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis ( MASH )
3个月前
已完结
Efficacy and safety of aldafermin for the treatment of metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis
3个月前
已完结
Early Real‐World Implementation of Once‐Weekly Insulin Icodec in Type 2 Diabetes
4个月前
已完结
皖公网安备34019202002308
